RIGLRigel Pharmaceuticals, Inc.

$541M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+13.5% YoY

Gross Profit

$29M96.5% margin

Operating Income

-$13M-43.5% margin

Net Income

-$13M-45.2% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+78.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$128M

Total Liabilities

$132M

Stockholders' Equity

-$4M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$26M	+13.5%
Gross Profit	$29M	$26M	+10.1%
Operating Income	-$13M	-$13M	+0.6%
Net Income	-$13M	-$14M	+2.4%

Revenue Segments

Gross product sales

$26M44%

Product sales, net

$19M31%

Revenues from collaborations

$11M19%

Development milestones

$5M8%

Research and development services and others

$4M7%

License revenues

$2M4%

Discounts and allowances

-$8M-13%

RIGL Q2 2022 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena